GeneDX stock fell over 45% on May 5, after the company reported first quarter revenue below analyst expectations and cut its full year 2026 revenue guidance from $540 to $555 million to $475 to $490 million. In February 2026, GeneDx reaffirmed its 2026 outlook and told investors that first quarter volume was tracking expectations and that expected collection rate seasonality had been reflected in its guidance. Block & Leviton is investigating.
Contact our attorneys for a no-cost case evaluation.